News

Adimab also announced the achievement of technical milestones from its ongoing collaborations with Novartis, Merck, Merrimack, and Genentech. Adimab CEO Tillman Gerngross said, "We are now expanding our

The filing of an investigational new drug application with the FDA for a monoclonal antibody that was optimized using Xencor’s XmAb antibody technology prompted the milestone payment. Xencor

Daclatasvir is an investigational NS5A replication complex inhibitor, and asunaprevir, an investigational NS3 protease inhibitor. In the Phase II open-label clinical trial (AI447-017), patients were divided into two

The single-blind, randomized trial is expected to enrol 72 obese patients, with a body mass index between 30 and 35kg/m². The primary objective of the placebo-controlled trial is

ALD518 is a monoclonal antibody to the pro-inflammatory cytokine IL-6, which is under Phase 2 development by Bristol-Myers Squibb for autoimmune diseases, and by Alder for cancer-related conditions.

Admet Predictor 6.0 now integrated with MedChem Designer offers graphical user interface improvements, expanded multidimensional graphics output and enhanced capabilities for exporting results. SLP Admet cheminformatics team leader

The company began the shipment of generic Fortamet (metformin hydrochloride extended-release tablets). Fortamet is indicated as an adjunct to diet and exercise to lower blood glucose for patients

The dexlansoprazole capsules are the generic version of Takeda’s Dexilant. As per the agreement, Par made a payment to Handa for the ANDA, giving it the exclusive rights

Carisbamate has previously been shown to have efficacy in trials for adult forms of epilepsy, such as partial onset seizures. IS is a form of epilepsy associated with